DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the CONCORD BIOTECH LIMITED (CONCORDBIO) share price today?

CONCORD BIOTECH LIMITED (CONCORDBIO) is trading at ₹1,342.8 on the NSE, down 0.24% on the day. Source: DocStoX.

What is the PE ratio of CONCORD BIOTECH LIMITED?

CONCORD BIOTECH LIMITED has a price-to-earnings (PE) ratio of 37.7 in the Healthcare sector.

What is the market capitalisation of CONCORD BIOTECH LIMITED?

CONCORD BIOTECH LIMITED has a market capitalisation of approximately ₹14,049 crore.

CONCORD BIOTECH LIMITED

CONCORDBIO·NSE·Healthcare

₹1,342.80▼ -3.20 (-0.24%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹1309.20

₹1352.70

52W₹987

₹198036%

Open

₹1346.00

High

₹1352.70

Low

₹1309.20

Prev Close

₹1346.00

Volume

90.3K

VWAP

₹1330.97

Snapshot

Key fundamentals

Market Cap

₹14,049 Cr

P/E Ratio

37.67Expensive

P/B Ratio

6.77

EPS

₹35.65

Book Value

₹192.81

ROE

20.50%Strong

ROCE

28.00%Efficient

Dividend Yield

0.82%

Debt / Equity

0.00Low

Face Value

₹1.00

52W High

₹1980.00

52W Low

₹987.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹300

▼ 77.7%downside

Trading at ₹1,343 — 78% above our estimate

BearFair valueBull

₹255₹300₹393

/100

Business quality — Solid

Growth 1Profitability 89Efficiency 50Valuation 65

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 3/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (21%)
Capital is working hard (ROCE 28%)

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

21% ROE fading to 12% over ~10 yrs, on ₹193 book

₹274

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹393

Analyst target

No analyst coverage

—

Blended fair value₹300

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (21%)
Capital is working hard (ROCE 28%)

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

37.7Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

20.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

28.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹14,049 Cr

P/B

6.77

EPS

₹35.65

Div Yield

0.82%

What changed

Recent changes

Foreign investors-0.3% stake last quarter
Domestic institutions+0.1% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 37.7×

Growth

Steady

+7% rev CAGR

Profitability

Excellent

20.5% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %43.8%

Turnover₹1201.74L Cr

Trades10,836

VWAP₹1330.97

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.3%

+11.3%

10Y

+16.0%

Profit

+3.1%

+2.1%

10Y

+14.1%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 28.2%

Watch-outs

Cons

The company has delivered a poor sales growth of 11.3% over past five years.
Company has high debtors of 159 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.26 pts; domestic institutions added 0.15 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

44%

Promoter

Promoters

44.1%0.00

Public

39.0%+0.14

FII / FPI

7.5%-0.26

DII

9.4%+0.15

Quarterly trend

Ownership over time

Q1 FY27

Promoter44.08%

FII7.53%

DII9.37%

Public39.04%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]